Liang Xu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2010419/publications.pdf

Version: 2024-02-01

65	11,254	32	63
papers	citations	h-index	g-index
69	69	69	24450
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Mechanism of RNA recognition by a Musashi RNA-binding protein. Current Research in Structural Biology, 2022, 4, 10-20.	2.2	17
2	Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR. Cancer Research, 2022, 82, P4-01-16-P4-01-16.	0.9	1
3	The RNA-binding protein HuR in human cancer: A friend or foe?. Advanced Drug Delivery Reviews, 2022, 184, 114179.	13.7	41
4	Abstract 1780: Functional inhibition of RNA-binding protein HuR reverses chemotherapeutic resistance in triple-negative breast cancer. Cancer Research, 2022, 82, 1780-1780.	0.9	0
5	Nano pom-poms prepared exosomes enable highly specific cancer biomarker detection. Communications Biology, 2022, 5, .	4.4	16
6	Crystal and solution structures of human oncoprotein Musashiâ€2 Nâ€ŧerminal RNA recognition motif 1. Proteins: Structure, Function and Bioinformatics, 2020, 88, 573-583.	2.6	10
7	Cover Image, Volume 88, Issue 4. Proteins: Structure, Function and Bioinformatics, 2020, 88, C1.	2.6	O
8	An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells. Molecular Cancer Therapeutics, 2020, 19, 2267-2277.	4.1	29
9	Identification and Validation of an Aspergillus nidulans Secondary Metabolite Derivative as an Inhibitor of the Musashi-RNA Interaction. Cancers, 2020, 12, 2221.	3.7	17
10	Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis. Science Translational Medicine, 2020, 12, .	12.4	79
11	Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H2S) donors as potent EGFR inhibitors against L858R resistance mutation. European Journal of Medicinal Chemistry, 2020, 202, 112522.	5.5	8
12	Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis. Communications Biology, 2020, 3, 193.	4.4	58
13	Inhibition of RNA-binding protein HuR reduces glomerulosclerosis in experimental nephritis. Clinical Science, 2020, 134, 1433-1448.	4.3	11
14	A small molecule STAT3 inhibitor, LLL12, enhances cisplatin†and paclitaxel†mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncology Reports, 2020, 44, 1224-1232.	2.6	3
15	A non-intrusive evaluation method for tumor-targeting characteristics of nanomedicines based on <i>in vivo</i> near-infrared fluorescence imaging. Journal of Materials Chemistry B, 2019, 7, 4751-4757.	5.8	6
16	Natural Product Gossypol and its Derivatives in Precision Cancer Medicine. Current Medicinal Chemistry, 2019, 26, 1849-1873.	2.4	40
17	HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A. Cancers, 2019, 11, 2014.	3.7	23
18	Human antigen R as a therapeutic target in pathological cardiac hypertrophy. JCI Insight, 2019, 4, .	5.0	38

#	Article	IF	Citations
19	Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy targeting pancreatic cancer stem cells. American Journal of Translational Research (discontinued), 2019, 11, 3543-3554.	0.0	9
20	Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures. Journal of Materials Chemistry B, 2018, 6, 1605-1612.	5.8	47
21	AKT-mediated phosphorylation of ATG4B impairs mitochondrial activity and enhances the Warburg effect in hepatocellular carcinoma cells. Autophagy, 2018, 14, 685-701.	9.1	52
22	Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins. BMC Cancer, 2018, 18, 809.	2.6	35
23	HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Scientific Reports, 2017, 7, 9694.	3.3	67
24	Design and synthesis of a novel photoaffinity probe for labelling EGF receptor tyrosine kinases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 954-959.	5.2	5
25	The fungal natural product azaphilone-9 binds to HuR and inhibits HuR-RNA interaction in vitro. PLoS ONE, 2017, 12, e0175471.	2.5	45
26	Identification of novel small molecule Beclin 1 mimetics activating autophagy. Oncotarget, 2017, 8, 51355-51369.	1.8	12
27	Human oncoprotein Musashi-2 N-terminal RNA recognition motif backbone assignment and identification of RNA-binding pocket. Oncotarget, 2017, 8, 106587-106597.	1.8	13
28	Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget, 2016, 7, 74043-74058.	1.8	86
29	A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel. Acta Biomaterialia, 2016, 43, 282-291.	8.3	33
30	Activation of HuR downstream of p38 MAPK promotes cardiomyocyte hypertrophy. Cellular Signalling, 2016, 28, 1735-1741.	3.6	38
31	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
32	DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites. Journal of Medicinal Chemistry, 2016, 59, 4152-4170.	6.4	20
33	Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. Oncotarget, 2016, 7, 62177-62193.	1.8	23
34	Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget, 2016, 7, 11708-11723.	1.8	58
35	Identification and Validation of Novel Small Molecule Disruptors of HuR-mRNA Interaction. ACS Chemical Biology, 2015, 10, 1476-1484.	3.4	120
36	Overexpression of $17\hat{l}^2$ -hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death. BMC Cancer, 2015, 15, 166.	2.6	19

#	Article	IF	CITATIONS
37	Natural product (â^')â€gossypol inhibits colon cancer cell growth by targeting RNAâ€binding protein Musashiâ€1. Molecular Oncology, 2015, 9, 1406-1420.	4.6	116
38	Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy. Biomaterials, 2015, 39, 131-144.	11.4	81
39	Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression. Oncotarget, 2015, 6, 12558-12573.	1.8	65
40	Bilayered near-infrared fluorescent nanoparticles based on low molecular weight PEI for tumor-targeted in vivo imaging. Journal of Nanoparticle Research, 2014, 16 , 1 .	1.9	8
41	An improved d-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. Journal of Controlled Release, 2014, 196, 272-286.	9.9	57
42	Antibody Against CD44s Inhibits Pancreatic Tumor Initiation and Postradiation Recurrence in Mice. Gastroenterology, 2014, 146, 1108-1118.e12.	1.3	118
43	Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells in vitro and in vivo. Breast Cancer, 2014, 21, 223-230.	2.9	20
44	HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS–JNK–autophagy pathway. Free Radical Biology and Medicine, 2014, 70, 194-203.	2.9	76
45	MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stem–like Cells and Breast Tumor Development. Cancer Research, 2014, 74, 6648-6660.	0.9	59
46	Double-layered hyaluronic acid/stearic acid-modified polyethyleneimine nanoparticles encapsulating (â^)-gossypol: a nanocarrier for chiral anticancer drugs. Journal of Materials Chemistry B, 2014, 2, 5238-5248.	5.8	30
47	Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells. Experimental Cell Research, 2014, 328, 379-387.	2.6	27
48	A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials, 2014, 35, 7146-7156.	11.4	52
49	Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival. International Journal of Clinical and Experimental Pathology, 2014, 7, 3235-44.	0.5	14
50	Natural Bcl-2 inhibitor (â^')â€" gossypol induces protective autophagy via reactive oxygen speciesâ€"high mobility group box 1 pathway in Burkitt lymphoma. Leukemia and Lymphoma, 2013, 54, 2263-2268.	1.3	26
51	HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s. Clinical Cancer Research, 2013, 19, 6703-6715.	7.0	65
52	Sorafenib Sensitizes (â^')-Gossypol-Induced Growth Suppression in Androgen-Independent Prostate Cancer Cells via Mcl-1 Inhibition and Bak Activation. Molecular Cancer Therapeutics, 2012, 11, 416-426.	4.1	44
53	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
54	Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. American Journal of Cancer Research, 2012, 2, 214-21.	1.4	171

#	ARTICLE	IF	CITATION
55	Tumor-targeted RNA-interference: functional non-viral nanovectors. American Journal of Cancer Research, 2011, 1, 25-42.	1.4	14
56	Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. American Journal of Cancer Research, 2011, 1, 128-43.	1.4	20
57	Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorganic and Medicinal Chemistry, 2010, 18, 3812-3822.	3.0	51
58	Natural Proteasome Inhibitor Celastrol Suppresses Androgen-Independent Prostate Cancer Progression by Modulating Apoptotic Proteins and NF-kappaB. PLoS ONE, 2010, 5, e14153.	2.5	87
59	Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target. Clinical Cancer Research, 2010, 16, 814-824.	7.0	85
60	The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy, 2010, 6, 1201-1203.	9.1	72
61	Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family Proteins. Current Drug Targets, 2010, 11, 699-707.	2.1	79
62	Celastrol Potentiates Radiotherapy by Impairment of DNA Damage Processing in Human Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1217-1225.	0.8	66
63	MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells. PLoS ONE, 2009, 4, e6816.	2.5	621
64	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Molecular Cancer Therapeutics, 2008, 7, 2192-2202.	4.1	171
65	Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis. Clinical Cancer Research, 2008, 14, 7701-7710.	7.0	53